This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
by Indrajit Bandyopadhyay
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
IARTNegative Net Change FMSPositive Net Change STEPositive Net Change
medical medical-devices
Here's Why You Should Retain American International Stock for Now
by Zacks Equity Research
AIG is positioned for growth on divestitures, cost controls, GenAI adoption and strong cash returns despite lagging the industry.
AIGNegative Net Change TRUPNegative Net Change SKWDNo Net Change HGNegative Net Change
artificial-intelligence insurance medical
Intuitive Surgical Stock Dips on Q4 Preliminary Revenue Results
by Zacks Equity Research
ISRG posts strong preliminary Q4 and full-year 2025 revenue growth, but shares dip as investors weigh procedure trends, margins and outlook.
BSXNegative Net Change ISRGNegative Net Change CAHNegative Net Change ATRCNegative Net Change
medical medical-devices
DexCom Stock Declines Following Strong Preliminary Q4 Results
by Zacks Equity Research
DXCM posts strong preliminary Q4 and full-year 2025 revenue growth, beating estimates, though shares slip after the announcement.
BSXNegative Net Change CAHNegative Net Change DXCMPositive Net Change ATRCNegative Net Change
medical medical-devices
President Trump's Great Healthcare Plan: How Insurers Are Impacted?
by Kaibalya Pravo Dey
President Trump's Great Healthcare Plan targets drug prices, subsidies and transparency. If implemented, it can boost competition in healthcare, impacting UNH, CNC, HUM & ELV.
UNHNegative Net Change HUMNegative Net Change CNCNegative Net Change ELVNegative Net Change
insurance medical
Here's Why You Should Hold DexCom Stock in Your Portfolio for Now
by Zacks Equity Research
DXCM looks poised for growth as CGM demand expands, G7 and One+ adoption accelerates, and strong Q4 results support a hold stance.
OMCLNegative Net Change DXCMPositive Net Change ATRCNegative Net Change PAHCPositive Net Change
medical medical-devices
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
by Indrajit Bandyopadhyay
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
IARTNegative Net Change FMSPositive Net Change STEPositive Net Change
medical medical-devices
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors?
by Ekta Bagri
Keros Therapeutics sharpens focus on KER-065 for DMD, cuts staff 45%, shelves cibotercept, and plans a phase II trial in Q1 2026 with cash runway into 2028.
SRPTNegative Net Change SLDBNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Erasca Stock Surges 42% in a Week: Here's What You Should Know
by Zacks Equity Research
ERAS stock jumps 42% in a week after early phase I solid tumors study data for ERAS-0015 shows encouraging responses, favourable safety and faster-than-expected enrollment.
ALKSPositive Net Change FOLDPositive Net Change KRYSPositive Net Change ERASPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Implied Volatility Surging for Vertex Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to VRTX stock based on the movements in the options market lately.
VRTXPositive Net Change
biotechnology biotechs medical
ANIP vs. TEVA: Which Drug Stock Is the Better Buy Right Now?
by Sundeep Ganoria
ANI Pharmaceuticals' rare disease growth, led by surging Cortrophin Gel sales, is outpacing Teva's slower sales momentum in this head-to-head stock comparison.
TEVANegative Net Change ANIPNegative Net Change ALVONegative Net Change
biotechs medical pharmaceuticals
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
PCRXNegative Net Change
biotechnology biotechs medical
Amazon & 3 More Stocks With Strong Interest Coverage Worth Buying
by Sumit Singh
AMZN, LRN, EAT and CAH boast strong interest coverage ratios, signaling solid financial footing and growth potential.
AMZNPositive Net Change CAHNegative Net Change EATNegative Net Change LRNNegative Net Change
consumer-discretionary medical retail
Hologic Leads Campaign to Emphasize Routine Cervical Cancer Screening
by Moumi Mondal
HOLX launches Ultimate Defense, a new U.S. campaign that urges routine Pap + HPV screening to boost awareness and help curb rising underscreening.
BSXNegative Net Change MDTNegative Net Change HOLXNegative Net Change
medical medical-devices
Weekly Option Windfall: Leading Medical Imaging Giant Offers Attractive Entry
by Bryan Hayes
The rise of GEHC reflects its strong positioning in imaging, patient monitoring, and pharmaceutical diagnostics.
GEHCNegative Net Change
artificial-intelligence hospitals medical medical-devices options pharmaceuticals smart-health
Does UnitedHealth's MA Pilot Signal a New Rural Support Model?
by Rajshree Sipani
UNH's six-month pilot speeds MA payments by ~50%, cutting cycles under 15 days to ease cash-flow strain for rural hospitals.
UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change
insurance medical
CLOV Reports MA Membership Growth, Signals GAAP Profitability in 2026
by Zacks Equity Research
Clover Health posts 53% AEP PPO membership growth, lifts total members to 153,000, and says the momentum positions it for GAAP net income profitability in 2026.
OMCLNegative Net Change ATRCNegative Net Change PAHCPositive Net Change CLOVNegative Net Change
medical medical-devices
Niche Focus & Regulation Shape the Future of Healthcare Firms
by Urbashi Dutta
CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.
CPIXNegative Net Change ICCCNegative Net Change NAIIPositive Net Change
medical
Apellis Stock Crashes 23% in a Week: Here's What You Should Know
by Zacks Equity Research
APLS stock plunges 23% in a week after reporting $190 million in preliminary Q4 U.S. net product revenues, as weaker Syfovre sales and mixed Empaveli uptake disappoint investors.
ALKSPositive Net Change FOLDPositive Net Change KRYSPositive Net Change APLSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Masimo Stock Declines Despite Solid Preliminary Q4 Revenues
by Zacks Equity Research
MASI posts strong fourth-quarter and full-year 2025 preliminary results with revenue and EPS above estimates, driven by core healthcare momentum.
BSXNegative Net Change CAHNegative Net Change MASIPositive Net Change IDXXPositive Net Change
earnings medical medical-devices
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
by Zacks Equity Research
QDEL's decent Q3 2025 results and expanding diagnostics portfolio support near-term growth despite respiratory reliance and payer risks.
BSXNegative Net Change IDXXPositive Net Change QDELNegative Net Change STEPositive Net Change
medical medical-devices
PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research
by Zacks Equity Research
PACB stock jumps as HiFi whole-genome sequencing becomes first-line in major SUDC research, highlighting adoption momentum.
BSXNegative Net Change IDXXPositive Net Change STEPositive Net Change PACBNegative Net Change
medical medical-devices
How Will Mounjaro and Zepbound Sales Aid LLY's Upcoming Q4 Results?
by Ahan Chakraborty
Eli Lilly's Q4 revenues are expected to reflect strong Mounjaro and Zepbound demand, as supply gains and global uptake offset pricing pressure.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
Zacks.com featured highlights include Universal Health Services, PNC Financial Services, Global Payments and BioMarin Pharmaceutical
by Zacks Equity Research
Universal Health Services anchors a Zacks value screen as low price-to-cash-flow stocks gain appeal amid policy uncertainty.
PNCPositive Net Change BMRNNegative Net Change UHSNegative Net Change GPNNegative Net Change
business-services finance medical
Bayer Stock Jumps on Nubeqa Outlook, Presents Pharma Strategy
by Zacks Equity Research
BAYRY jumps 6.6% after partner Orion said Nubeqa sales tied to Bayer could top ???1B long term. Bayer also announced pharma priorities at J.P. Morgan Healthcare Conference.
JNJNegative Net Change BAYRYPositive Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals